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This work aims to employ fused deposition modelling 3D printing to fabricate immediate 
release pharmaceutical tablets with various model drugs. It investigates the addition of non-
melting filler to methacrylic matrix to facilitate FDM 3D printing and explore the impact of i) 
the nature of filler, ii) compatibility with the gears of the 3D printer and, and iii) polymer: filler 
ratio on the 3D printing process. A specially developed filament based on pharmaceutically 
approved methacrylic polymer (Eudragit E) and thermally stable filler, TCP (tribasic calcium 
phosphate) was optimised. Four model drugs (with different physicochemical properties were 
included into ready-to-use mechanically stable tablets with immediate release properties. 
Amongst the investigated fillers in this work, directly compressible lactose, spray-dried lactose 
and microcrystalline cellulose showed a level of degradation at 135oC whilst talc and TCP 
allowed consistent flow of the filament and a successful 3D printing of the tablet. Following 
the two thermal processes (hot melt extrusion (HME) and fused deposition modelling (FDM) 
3D printing), drug contents were 94.22%, 88.53%, 96.51% and 93.04% for 5-ASA, captopril, 
theophylline and prednisolone respectively. XRPD indicated that a fraction of 5-ASA, 
theophylline and prednisolone remained in the crystalline form whilst captopril was in 
amorphous form. By combining the advantages of thermally stable pharmaceutically approved 
polymers and fillers, this unique approach provides a low cost production method for on 
demand manufacturing of individualised dosage forms. 
Keywords: Fused filament fabrication; Personalized; Patient-specific; Three dimensional printing;  
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Advances in the field of pharmacogenomics have provided the impetus for personalised dosage 
forms to suit an individual patient’s need (Ginsburg and Willard, 2009; Hamburg and Collins, 
2010; Tremblay and Hamet, 2013). In the future it is highly likely that the trend will shift 
towards the fabrication of unit dosage forms closer to patients; at the point of dispensing, or 
even at the point of use. This is in line with current trends which encourage the provision of 
efficient outpatients’ services which can be controlled digitally and remotely (McLean et al., 
2013). The demand for versatile and adjustable manufacturing technologies that are capable of 
overcoming the rigidity and the high cost of traditional manufacturing methods of 
individualised oral tablets for a limited number of patients is also rising (Yang et al., 2016; Yu 
et al., 2015). Unlike conventional tablet compression methods, 3D Printing technologies are 
capable of fabricating small number of dosage forms, reduce the number of steps and 
experienced operators involved in manufacturing, and eliminate the need for designated and 
expensive facilities (Skowyra et al., 2015).  
Three-dimensional (3D) printing technologies are set to revolutionise the individualisation of 
dosage forms at the point of dispensing or use (Sanderson, 2015). These highly attractive 
technologies produce 3-dimensional objects of virtually any shape under the control of a 
computer software. Powder based 3D printing was first adapted to fabricating tablets with 
immediate (Pyrce Lewis et al., 2011; Wang et al., 2006; Yu et al., 2007), delayed release 
profiles (Fuh et al., 1999). In late 2015, the FDA approved the first 3D printed fast-dissolving 
tablets for treatment of epilepsy, Spritam® (levetiracetam) (Aprecia, 2014; Yoo et al., 2014). 
However, the technology produces tablets of poor mechanical properties and surface 
imperfections (Katstra et al., 2000b; Pham and Gault, 1998; Yu et al., 2009). Powder-
specialised facilities with potential wastage are less suitable for small-scale production in a 
community or hospital pharmacies (Huang et al., 2013). 
Semi-solid Extrusion (EXT) 3D printing, has been explored recently for the fabrication of 
tablets using semi-solid starting materials through a syringe based tool-head. EXT 3D printing 
is capable of fabricating bilayer tablets (Khaled et al., 2014a) or polypills with different release 
profiles at room temperature (Khaled et al., 2015a, b). Nonetheless, the technology requires 
post-operating drying process and yields tablets of high friability (Katstra et al., 2000a; Khaled 
et al., 2014b).  FDM 3D printing is an attractive platform because it offers mechanically stable 
1. Introduction  
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printed structures (Pietrzak et al., 2015), with high resolution (30-200 µm) (Goyanes et al., 
2015a) and a ready-to-use printed objects from the printer platform with no additional post-
processing steps (Goyanes et al., 2015b; Skowyra et al., 2015). Due to the expiration of patents 
of this technology and the availability of low cost FDM printers, this technology is likely to be 
widely utilized by a large number of consumers.  
The potential of FDM 3D printing incorporating drugs into commercially available filaments 
(Goyanes et al., 2014a; Goyanes et al., 2014b; Goyanes et al., 2015b; Skowyra et al., 2015) has 
been explored previously. Nonetheless, all those studies highlighted several challenges 
involved in employing printing technique for pharmaceutical applications. The use of elevated 
temperatures (185-220◦C) and limited drug loading (0.063-9.5% w/w (Goyanes et al., 2014a; 
Goyanes et al., 2014b; Goyanes et al., 2015b; Skowyra et al., 2015) renders it less suitable for 
many drugs particularly thermo-labile ones. FDM 3D printing has been also restricted to a 
number of biodegradable thermoplastic polymers such as polylactic acid (PLA) (Sandler et al., 
2014) and polyvinyl alcohol (PVA) (Goyanes et al., 2014a; Goyanes et al., 2014b; Goyanes et 
al., 2015b; Skowyra et al., 2015) in comparison to a wide variety of choices for conventional 
tabletting. Despite the attractive properties of PVA (Morita et al., 2000) and PLA(Hamad et 
al., 2016), the use of high polymer ratio in combination with the need for high molecular weight 
of the polymers generates polymeric matrices with limited porosity, thus resulting in extended 
drug release patterns (Goyanes et al., 2014a; Goyanes et al., 2014b; Goyanes et al., 2015a; 
Goyanes et al., 2015b; Sandler et al., 2014; Skowyra et al., 2015).  
Approximately 40% of drug delivery products are taken orally and 70% of these are immediate 
release formulations (GBIResearch, 2012; Marketsandmarkets, 2013). Hence, it is of great 
interest to adapt FDM 3D printing to pharmaceutical materials and different drug molecules 
for immediate release of the final product. Eudragit EPO is a robust drug delivery carrier with 
taste masking, moisture protection and good mechanical properties (Shishu et al., 2010). The 
branched nature of the polymer however gives it a lower glass transition temperature (Tg) value 
compared to linear copolymers (Tapan Parikh, 2014). The ability to adapt polymers with such 
low Tg values to FDM 3D printing is a major challenge. We have reported employing Eudragit 
EPO for production of immediate release theophylline tablet (Pietrzak et al., 2015). However, 
the suitability of this polymer to fabricate immediate release tablets when loaded with 
molecules of different physicochemical properties is still not established. In this paper, we 
introduced the addition of a non-melting filler to methacrylic matrix to facilitate FDM 3D 
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printing and assessed the impact of: i) the nature of filler, ii) compatibility with the gears of the 
3D printer and, and iii) polymer: filler ratio. Furthermore, we exploited the optimised filament 
from this approached and utilized it as a generic platform to accommodate four model drugs 
with acidic (5-ASA and captopril), basic (theophylline) and neutral (prednisolone) nature and 
different melting points. We have also evaluated their stability during the thermal processes 
and the quality of resultant 3D printed tablets.  
2. Materials and methods 
2.1  Materials 
Theophylline (Tm=273°C) was purchased from Arcos (UK). Eudragit EPO was donated by 
Evonik Industries (Darmstadt, Germany). Triethyl citrate (TEC), tri-Calcium phosphate (TCP), 
talc, 5-ASA (Tm=283°C), captopril (Tm=103°C) and prednisolone (Tm=230°C) were supplied 
by Sigma-Aldrich (UK). Scotch blue painter’s tape 50 mm was supplied by 3M (Bracknell, 
UK). Spray-dried lactose, directly compressible lactose Ludipress® and microcrystalline 
cellulose (MMC) Avicel® were purchased from FMC biopolymers (UK).  
2.2  Preparation and optimisation of filaments  
The impact of adding a non-melting component to the methacrylic matrix at different ratios 
using different pharmaceutical fillers on the production of compatible filament was assessed. 
The filament was considered compatible with the gears of the FDM 3D printer’s head if it 
allows continuous flow from the hot nozzle (i.e. without breaking within the gears of the 
printer’s head (brittle filaments) or bending between the gears and the hot nozzle (flexible 
filament). 
The screening of commonly used fillers in tablet manufacturing was conducted to explore their 
suitability with the immediate release polymer Eudragit E. Additives examined in the study 
were; microcrystalline cellulose (MCC), talc, tri-calcium phosphate (TCP) as well as spray 
dried (SD) and directly compressible (DC) lactose.  
To assess the suitability of the different fillers, filaments with Eudragit EPO (plasticised by 
6.5% w/w TEC) and different fillers at ratio 50:50 were first utilised using HME as specified 
below. In order to optimise the flexibility of Eudragit EPO matrix, different TEC (plasticiser) 
concentrations were scanned at 5%, 6%, 6.5% and 10% of polymer weight and filaments were 
produced at 50:50 ratio of Eudragit EPO matrix and a non-melting filler (TCP). To assess the 
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influence of concentration of non-melting filler, different ratios of TCP: Eudragit EPO matrix 
(containing 6.5% TEC as plasticiser) ratios were screened: 0:100, 20:80, 40:60, 50:50 and 
60:40. An optimised ratio of Eudragit E: TEC: TCP (46.75:3.25:50) were concluded based on 
the filler’s stability, compatibility with the gears of the printer head and rheology of the filament 
at the printing temperature (see Results and discussion section). Later, the optimised ratio was 
employed to produce drug loaded filaments for 4 model drugs (5-ASA, captopril, prednisolone 
or theophylline) [ratio Eudragit E: TEC: TCP: drug (46.75:3.25:37.5:12.5)], where the drug 
was considered as a replacement for a portion of the filler.  
Approximately 10 g of materials was accurately weighed and added gradually to counter flow 
twin-screw hot melt extruder, HAAKE MiniCTW (Karlsruhe, Germany). To allow 
homogeneous distribution of the powders, the molten mass was mixed in the extruder for at 
least 5 min prior to extrusion. The specific temperature of initial feeding and extrusion for the 
filament were 100 and 90 ◦C respectively. A torque control of 0.8 Nm was used to extrude out 
the filaments. Filaments were stored in sealed plastic bags at room temperature before 3D 
printing.  
2.3 Design and printing of tablets 
Tablets were constructed with the pre-prepared filaments using a commercial FDM 3D printer 
equipped with 0.4mm nozzle size. The templates used to print the tablets were designed in 
caplet shape using Autodesk® 3ds Max® Design 2012 software version 14.0 (Autodesk, Inc., 
USA). The design was saved in a stereolithography (.stl) file format and was imported to the 
3D printer’s software, MakerWare Version 3.9.1.1143 (Makerbot Industries, LLC., USA). 
Tablets were printed using modified settings of the software for PLA: as follows: type of 
printer: Replicator 2X; type of filament: PLA; resolution: standard; speed of extruder 90 mm/s 
while extruding and 150 mm/s while traveling; infill: 100%; height of the layer: 200 µm. No 
supports or rafts were utilized. The temperatures for the nozzle and build plate of the 3D printer 
were 135 oC and 60 oC respectively. Blue Scotch painter’s tape was applied to the build 
platform to facilitate the adherence of the printed object during FDM 3D printing. A series of 
tablets were printed individually in the following dimensions: Length × Width × Height 
(12x4.59x4.71 mm).  
2.4 Thermal analysis 
 Samples of (raw materials, extruded filaments and printed tablets) were characterised using 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). For DSC 
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analysis, a differential scanning calorimeter DSC Q2000 (TA Instruments, Elstree, 
Hertfordshire, UK) with a heating rate of 10 °C/min was used. Samples were heated to 100 °C 
for 5 min to exclude the effect of humidity then cooled to −20 °C. This was followed by a heat 
scan from −20 °C to 300 °C. Analysis was carried out under a purge of nitrogen (50 mL/min). 
The data was analysed using TA 2000 analysis software. Standard 40 µL TA aluminium pans 
and pin-holed lids were used with an approximate sample mass of 5 mg. All measurements 
were carried out in triplicates. 
For TGA analysis, raw materials, model drugs, extruded filaments and 3D printed tablets were 
measured using a TGA/SDTA851e Mettler Toledo (Leicester, UK). Samples (5 mg) were 
placed in 40 µL aluminium pans and were then heated from 25 to 500°C using 10°C/min as a 
heating rate. The thermal decomposition (or degradation) profile was analysed using STARE 
software version 9.00. The experiments were carried out under nitrogen gas flow of 50 mL/min. 
All measurements were carried out in triplicates. 
2.5 X-ray Powder diffractometry (XPRD) 
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to 
assess the physical form of model drugs in Eudragit E, TCP, Eudragit E:TEC filament, blank 
and drug-loaded filaments, and 3D printed tablets. Samples were scanned from 2Theta (2θ)= 
5° to 50° using 0.01° step width and a 1 second time count. The divergence slit was 1 mm and 
the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a 
voltage of 30 kV. Filament emission was 10 mA using a scan type coupled with a two 
theta/theta scintillation counter over 30 min.  
2.6 Rheological properties of filament 
The rheological properties of TCP filaments were studied using an AR2000 rheometer (TA 
instruments, USA), equipped with parallel plate geometry (diameter 25 mm). The strain (ε) 
sweep tests were conducted at 135°C, at an angular frequency of ω=10 rad/s.  
2.7  Scanning Electron Microscopy 
The surface morphology of the filaments and the printed tablets was assessed using a Quanta-
200 SEM microscope at 20 kV. All samples for SEM visualisation were placed on a metallic 
stub and gold plated using a JFC-1200 Fine Coater (Jeol, Tokyo, Japan). Photographs of the 
tablets were captured with a Canon EOS-1D Mark IV (Canon Ltd, Japan). 
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2.8 Characterisation of the tablets properties 
The hardness of 6 tablets was measured using a TBH 200 (Erweka GmbH, Heusenstamm, 
Germany). The mean crushing strength was determined, whereby an increasing force was 
applied to the tablet until it was fractured or deformed.  
In order to assess the friability of the tablets, 20 tablets were randomly selected, weighed and 
placed in a friability Tester Erweka type TAR 10 (Erweka GmbH, Heusenstamm, Germany) 
and the drum was then rotated at 25 rpm for 4 min. The tablets were reweighed and the 
differences in weight were calculated and displayed as a percentage of the original sample 
weight. In order to assess weight uniformity, 10 tablets were randomly selected and weighed. 
The average weights were measured and the percentage deviation of the individual tablets from 
mean was determined. 
To assess the impact of both HME and FDM 3D printing on drug contents, 3 tablets from each 
formulation, were randomly selected and weighed. Tablets were then individually placed in a 
1000 mL volumetric flask containing 0.1 M HCl and sonicated for 2 hours. The solution were 
filtered through 0.22 μm Millex-GP syringe filters (Merck Millipore, USA) and prepared for 
HPLC analysis.  
Drug contents in relevant samples were assessed using an Agilent UV-HPLC 1260 series 
(Agilent Technologies, Inc., Germany) equipped with XTerra RP 18 column (150 x 4.6 mm, 
5µm particle size) (Waters, Ireland)  for theophylline and Kinetex C18 column (100 × 2.1 mm, 
particle size 2.6 μm) (Phenomenex, Torrance, USA) for 5-ASA, prednisolone and captopril  at 
temperature 26°C. The mobile phase was (acetonitrile: water adjusted to pH 3 with 
orthophosphoric acid, at ratios 40:60, 90:10 and 80:20 for 5-ASA, prednisolone and captopril 
and a flow rate of 0.5 mL/min. For theophylline, the mobile phase was composed of ammonium 
acetate buffer, methanol and acetonitrile (86:7:7) at a flow rate 1 mL/min. The injection volume 
was 20 µL and a stop time was 10 min per sample.  
In vitro disintegration and drug release studies. Tablet disintegration was carried out using an 
Erweka ZT220 disintegration testing apparatus (Erweka GmbH, Heusenstamm, Germany). Six 
tablets were randomly selected, weighed and each placed in a basket rack assembly having six 
cylinders and the tablets were covered with discs. The basket rack assembly was then immersed 
into a beaker containing 0.1M HCl at 37 C̊. The exact time for all tablets to fully leave the mesh 
was visually noted. 
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In vitro drug release studies was investigated using a USP II Erweka DT600 dissolution tester 
(Erweka GmbH, Heusenstamm, Germany). Three tablets were randomly selected and 
individually placed in the dissolution vessels each containing 900 mL of 0.1M HCl at 50 rpm 
and 37±0.5 ◦C. Aliquots (4 ml) were manually collected using 5ml Leur-Lock syringes at 0, 5, 
10, 15, 20, 25, 30, 40, 50 and 60 minutes time intervals and filtered through a Millex-HA 0.45 
µm filter. Each aliquot withdrawn was replaced with 4 mL of 0.1M HCl. The absorbance of 
the samples were finally measured using a Jenway UV spectrophotometer (Bibby Scientific 
Ltd, UK) at λmax of 232, 204, 247 and 272 nm for 5-ASA, captopril prednisolone and 
theophylline respectively.  
Statistical analysis 
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results. 
Differences in results of p <0.05 were considered to be significant. 
 
3. Results and discussion 
Fig. 1 illustrates the production of methacrylic tablets via FDM 3D printing with a focus on 
immediate release properties. The process involves; firstly, the development of drug-loaded 
filaments via processing a physical mixture of melting and non-melting components of the 
polymer, drug and excipients through HME at 100 °C (Fig. 1a); secondly the utilization of 
computer to design capsule-shaped tablets (Fig. 1b); thirdly, feeding the drug-loaded filaments 
into an FDM based 3D printer (Fig. 1c) and finally, the fabrication of 3D printed tablets at 135 
°C (Fig. 1d). 
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Fig. 1. Schematic illustration of the fabrication of immediate release 3D-printed tablet. (A) Materials 
mixture (drug, methacrylic polymer and TCP) are processed through HME to produce (B) a uniform 
filament. (C) Stereolithographic file is created via CAD software and (D) benchtop FDM 3D printer is 
used to (E) fabricate drug loaded immediate release tablet. 
 
Initially filament based only on Eudragit EPO was examined. Although it was possible to 
extrude this filament from the printer nozzle, a collapsed structure was yielded with poor 
features and deformable build. Such a behaviour is related to the branched nature of the 
methacrylic polymer that gave a lower (Tg) value compared to linear copolymers (Tapan 
Parikh, 2014). During FDM 3D printing, filaments passing through a heated nozzle are turned 
into semi-solids before solidifying to form 3D printed structures at room temperature. One 
solution is to add a component with a higher melting than the operating temperature of HME 
and FDM 3D printing. Several pharmaceutical fillers were screened for suitability of HME 
filament formulation and FDM 3D printing. DC and SD lactose types as well as MCC showed 
poor flow during FDM 3D printing and resulted in discoloured and incomplete printed 
structures. TGA studies (Fig. 2a) elucidated the thermal degradation of MCC following 
evaporation of MCC bonded water and the degradation of the cellulose skeleton (> 310 oC) 
(Huang, 2012). Both DC and SD lactose suffered a weight reduction above 100oC due to water 
loss followed by lactose backbone degradation (> 240 oC). TCP and talc appeared stable as 
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supported by the TGA and demonstrated their thermal stability at temperatures >250 oC. This 
can be correlated to their high melting points (>1000oC) (Enderle et al., 2005). 
 
Fig. 2. Thermal analysis of Eudragit EPO based 3D printing filaments. (A) Thermal degradation profiles 
for different fillers screened for suitability with Eudragit EPO, (B) DSC thermograph for different 
plasticizer concentrations incorporated in Eudragit EPO filament, (C) DSC thermograph for different 
TCP concentrations (non-melting component) incorporated in the Eudragit EPO filament (containing 
6.5% TEC as plasticiser) and (D) DSC thermograph of different 3D printed tablets containing the model 
drugs; 5-ASA, captopril, prednisolone or theophylline. 
 
While both TCP and talc proved to be suitable thermostable fillers, it was decided to focus on  
TCP as a model filler. Thereafter, the level of plasticity of filament was optimised by modifying 
the concentration of the plasticizer (TEC) 5-10% yielding filaments of Tg range of 29.7- 46.5 
oC (Fig. 2b). While all the range facilitated the production of the filaments, poor flow of the 
filament were achieved at 5% and 10% due to frequent breakage of the brittle filament or poor 
pressure on the nozzle of the excessively flexible filament during 3D printing, respectively. 
The influence of non-melting component on the structure, Tg and rheological behaviour of the 
filament has been studied. SEM images showed that the extruded (1.75 mm) filament of 
Eudragit EPO (TCP-free) had a smooth surface and consistent cross sectional structure (Fig. 
3a). However, it proved unsuitable for 3D printing process. Upon the addition of increasing 
concentrations of TCP, the surface of extruded filaments (200 μm) appeared rough with voids 
and irregular pores between layers (Fig. 3b-e). The roughness and density of voids was also 
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found to increase at higher percentages of TCP incorporated into the formulae. DSC 
thermographs on the other hand (Fig. 2c) revealed that the glass transition temperature (Tg) of 
polymeric matrix was not affected significantly by the incorporation of TCP at all of its ratios 
(0-60%) (p>0.05) and the Tg remained approximately 30 oC. This suggests that TCP particles 
remained suspended in Eudragit EPO matrix with minimal interference on the Tg of the 
methacrylic filament.  
 
Fig. 3. Impact of TCP concentration on the morphology of Eudragit EPO filaments; (a) SEM images of 
filaments with no TCP, (b) SEM image of TCP alone and (c-f) SEM images of filament incorporating 
TCP at a ratio of 20, 40, 50 or 60% respectively. 
The filament behaviour within the high temperature nozzle of the 3D printer could be related 
to the rheological behaviour of the filament at elevated temperatures. Fig. 4 compares the 
rheological properties of the polymer matrices. All filaments exhibited a predominantly viscous 
character with G'<G" and the introduction of TCP was found to monotonically enhance the 
viscoelastic behaviour, as expected for filled polymeric systems (Yurekli et al., 2001). At high 
deformations all systems deviated from the linear viscoelastic region, exhibiting strain 
thinning. The critical strain amplitude for strain thinning systematically decreases with filler 
loading, consistent with general trends established for composites and nanocomposites 
materials (Yurekli et al., 2001). To that end, the 60% w/w TCP filament can withstand a 
maximum stress value of 21 kPa (at γ=2) compared to 45kPa (at γ=18), 50 kPa (at γ=29) and 
41kPa (at γ=44) for the 50 %, 40 % and 0% w/w TCP filament, respectively (Supplementary 
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data, Appendix A, Fig. S1). This indicates that for FDM 3D printing the filament must 
withstand the stress exerted by the printer gears while having a considerably high viscosity 
capable of solidifying uniformly to withstand increasing weight of next layer during the 
printing process. Due to these findings a TCP ratio of 50% was used thereafter during the study.  
 
Fig. 4. Storage (G') and loss (G'') moduli of CAP based filaments as a function of the strain (T=135 oC, 
ω=10 rad·s-1). 
 
The printing temperature in this study (135°C) is noticeably lower than those recommended by 
3D printer manufacturer (230°C) (Makerbot, 2013), hence making printing via bridging HME 
with FDM 3D printing suitable for a wider spectrum of materials.  
In order to prove the suitability of this model filament for different drug candidates, four model 
drug molecules with different physicochemical properties; 5-ASA, captopril, prednisolone and 
theophylline were incorporated in the formulation at a concentration of 12.5% w/w.  
DSC thermographs indicated that drugs had minor plasticizing effect on the filaments. 
However, the thermoplastic behaviour of Eudragit EPO was not altered significantly at the 
loadings studied (Fig. 2d). The incorporation of the drugs into the filaments did not hinder the 
FDM 3D printing process and caplets were successfully fabricated from all drug-loaded 
filaments.  
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Fig. 5. XRPD patterns of Eudragit EPO, TPC, model drugs and drug loaded filaments and 3D printed 
tablets for a) 5-ASA, b) captopril, c) prednisolone and d) theophylline. 
XRPD patterns confirmed the amorphous nature of Eudragit EPO whilst TCP remained 
crystalline across all the tested samples. XRPD patterns of both HME produced filaments and 
3D printed tablets indicated the presence of intensity peaks at (2θ)= 7.9, 15 (Andrews et al., 
2008; Bruce et al., 2005) for 5-ASA,  (2θ)= 14.7, 17.6 for prednisolone (Nishiwaki et al., 2009; 
Sabzevari et al., 2013) and (2θ)= 7, 12 (Liu et al., 2007) for theophylline. This suggests that a 
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fraction of these drugs remained in the crystalline form in filament and 3D printed tablets. In 
case of captopril, the absence of peaks at (2θ)=  10,12 and 20 (Khaled et al., 2015c) in the 
extruded filament as well as the 3D printed tablet indicated that the majority of captopril 
remained amorphous. It is possible that the use of a HME and FDM temperatures (100 and 135 
oC respectively) close or above the melting point of captopril (103 oC) resulted in complete 
melting of the drug and yielded a non-crystalline filament matrix.   
The weight uniformity, drug content and friability of the caplets produced were evaluated 
(Table 1). HPLC analysis indicated that HME process is the major degradation step rather than 
the FDM 3D printing step. It is possible that during filament preparation the model drugs are 
exposed to relatively high temperature (100 oC) for much longer period of time (up to 10 min) 
than that in hot nozzle of the 3D printer (fraction of a second) .The drug contents was >93% 
for 3D printed tablets of theophylline, prednisolone and 5-ASA. In case of captopril, its content 
was lower (88%), which might be related to drug degradation during HME process and FDM 
3D printing. This was confirmed with a reduction in captopril tablet weight at 135 oC as 
established in TGA data (Fig. 6). Although the weights of the different formulations were found 
to vary slightly between formulations, there were no significant differences in the dimensions 
of the printed tablets (p> 0.05) (Table 1). Tablets were designed in caplet shape to enhance 
patient compliance (Overgaard et al., 2001; Schiele et al., 2012). They were made of stacked 
200 μm thick layers as it can be observed with SEM images (Fig. 7). The dose of the caplets 
can be adjusted using the software by modifying the volume of the printed drug delivery system 
(Pietrzak et al., 2015). Thus, FDM 3D printing is a highly attractive in modifying the dose to 
suit patients’ individual needs. 
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Fig. 6. Thermal degradation profiles for the used model drugs, drug loaded filament and 3D printed 
tablet; a) 5ASA, b) captopril, c) prednisolone and d) theophylline. 
 
Table 1. Summary of weight uniformity, drug content, friability, disintegration time and the 
dimensions of the different 3D printed tablets.  
Drug 
 
Weight 
Uniformity 
±SD (mg) 
Drug content 
±SD (%) 
Friability 
(%) 
Disintegration 
time (min) 
Dimensions   
Filament Tablet L (mm) W (mm) H (mm) 
5-ASA 203.6±16.7 94.61±1.42 94.22±1.15 0 11.72 ± 0.12 3.91 ± 0.12 4.90 ± 0.03 11.72 ± 0.12 
Captopril 226.1±18.4 88.15±0.78 88.53±0.02 0 11.71 ± 0.22 4.105 ± 0.25 4.86 ± 0.12 11.71 ± 0.22 
Prednisolone 232.6±17.7 97.18±0.61 96.51±1.38 0 11.63 ± 0.14 4.21 ±0.13 4.90 ± 0.12 11.63 ± 0.14 
Theophylline 194.8±10.8 95.04±1.52 93.04±0.55 0 11.69 ± 0.18 4.00 ± 0.34 4.92 ± 0.18 11.69 ± 0.18 
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Fig. 7. SEM images of 3D printed tablets containing theophylline; (A) surface morphology (B-D) cross-
sections.  
Analysis of the drug content of 3D printed tablets demonstrated the capability of the bench-top 
FDM printer in fabricating tablets with acceptable in-batch drug content variations analogous 
to findings of Pietrzak et al. (2015). (Table 1). The friability revealed no variations and was 
demonstrated to be 0% for all the formulation. Unlike tablets generated from other 3D printed 
technologies such as EXT (Khaled et al., 2014a) and powder-based 3D printing (Katstra et al., 
2000b; Yu et al., 2009), the friability of tablets generated using via FDM 3D printing tends to 
be very low or even zero (Goyanes et al., 2014a; Goyanes et al., 2015c; Pietrzak et al., 2015). 
Such mechanical resistant was also observed in metal/polymer composite filaments (Hwang et 
al., 2014) and gives an indication on the capability of FDM 3D printing in unit fabrication 
without additional post manufacturing processing. This makes the technology highly suitable 
for on-demand dosage form manufacturing. 
17 
 
 
Fig. 8. (A) Photographs of 3D printed tablets containing the model drugs; 5-ASA, captopril, 
prednisolone or theophylline, (B) disintegration time for the different 3d printed tablets (n=6) and (C) 
drug release from 3D printed Eudragit EPO tablets (n=3). 
It was possible to maintain the caplet shape for all model drugs (Fig.8 a) with disintegration 
time of less than 15 minutes (Fig. 8b). The distinctive brown colour of 5-ASA tablet may 
suggest the degradation of 5-ASA. However, HPLC data and TGA did not showed a significant 
degradation. Such colour can attributed to the grey/pink colour of pure 5-ASA crystals 
(Comission, 2010). The in vitro release patterns from Eudragit EPO printed tablets indicated 
that the majority of the drug was released within 30 min (Fig. 8c). As the dissolution of all 
model drugs was carried out at sink condition, the drug release was mainly dictated by the 
dissolution rate of the polymer. At gastric pH, the dimethylaminoethyl side chains of Eudragit 
EPO ionises leading to electrostatic repulsion between the cationic polymeric chains. 
Consequently, this increases the polymeric chain spaces thus allowing the dissolution of the 
polymer and drug release. All the different tablets released more than 85% of its drug content 
within 30 minutes.  
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4. Conclusions 
A novel approach based on the addition of a pharmaceutical grade non-melting filler (TCP) to 
allow a consistent flow from FDM 3D printer’s nozzle and facilitate a reproducible 3D printing 
was presented. An optimal range of non-melting component of (20-50%) within the filament 
composition enables the fabrication of well-defined caplets. Filaments produced via this 
approach were suitable for incorporating four model drugs of different physicochemical 
properties. HPLC indicated above 94% of drug contents remained intact in the tablet following 
the two thermal processes for theophylline, 5-ASA and prednisolone, whilst a significant drop 
in captopril content was observed and might be attributed to thermal degradation. The tablets 
fabricated possessed excellent mechanical strength and acceptable in-batch variations. The 
approach presented involving FDM 3D printing offers several advantages for developing 
personalised dose on demand. These include i) use of low cost printer and widely available and 
approved pharmaceutical ingredients, ii) suitability of different drug molecules, iii) significant 
improvement on morphology and mechanical resistance (friability), and iv) absence of post-
printing finishing and drying steps. 
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